Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16448339 | 0.93 | PDE4B (0.52) | PDE4BRAB9ATSHRPTK2SMN1; SMN2 | |
| SCHEMBL17784207 | 0.93 | PDE4B (0.55) | PDE4BTSHRPTK2MEN1MAPT | |
| SCHEMBL16448257 | 0.91 | PDE4B (0.53) | PDE4BTSHRMEN1MAPTKMT2A | |
| SCHEMBL17784235 | 0.90 | PDE4B (0.56) | PDE4BTSHRMEN1MAPTKMT2A | |
| SCHEMBL19118056 | 0.89 | PDE4B (0.60) | PDE4BTSHRMAPTGGPS1 | |
| SCHEMBL17784209 | 0.88 | PDE4B (0.58) | PDE4BTSHRSMN1; SMN2MEN1MAPT | |
| SCHEMBL16447934 | 0.86 | PDE4B (0.54) | PDE4BSMN1; SMN2 | |
| SCHEMBL17784202 | 0.85 | PDE4B (0.53) | PDE4BMEN1KMT2A | |
| SCHEMBL17784226 | 0.84 | PDE4B (0.52) | PDE4BSMN1; SMN2MAPT | |
| SCHEMBL17784217 | 0.84 | PDE4B (0.60) | PDE4BSMN1; SMN2MEN1KMT2AGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688683-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2017-06-27 | — | — | US | disclosed |
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | PDE4A, PDE4B, TYMP | PDE4B 2/4885RAB9A 3544/4885TSHR 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.